The global LyophilizedDrugs Market, by Drug Class (Anti-infective, Antineoplastic, Diuretics,Proton Pump Inhibitor, Anesthetic, Anticoagulant, NSAID’s (Nonsteroidalanti-inflammatory drugs), and Others), by Indication (Infectious Disease,Autoimmune Disease, Gastrointestinal Disease, Cancer, and Others), by PackagingType (Vial, Injection, and Cartridge), and by region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) is estimated to bevalued at US$ 322.9 Billion in 2018, and is projected to exhibit a CAGR of7.1%, during the forecast period (2018-2026), as highlighted in a new reportpublished by Coherent Market Insights.
Increasing number of product launchesfor lyophilized drugs is contributing to growth of the global lyophilized drugsmarket. For instance, in July 2015, Sandoz AG launched a generic version ofANGIOMAX (bivalirudin) for injection in the U.S market after completing asupply and distribution agreement with The Medicines Company. The drug is usedas an anticoagulant agent for treating patients with unstable angina,undergoing percutaneous transluminal coronary angioplasty (PTCA), andpercutaneous coronary intervention (PCI). Increasing focus of manufacturers onthe development of innovative lyophilization technologies and services, inorder to manufacture lyophilized drug with utmost quality and capacity, iscontributing to lyophilized drugs market growth.
For instance, in May 2015, SymbiosisPharmaceutical Services, Sterile manufacturing CMO, announced to offer a newbulk lyophilization (freeze drying) service, in order to meet utmost quality inthe manufacturing of bulk intermediates and APIs by lyophilization. Thus,development of such novel service platforms isw creating opportunity formanufacturers to expand in lyophilized drugs, thus, aiding in growth of themarket in the near future.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2930
Browse 35 Market Data Tables and38 Figures spread through 208 Pages and in-depth TOC on "Global LyophilizedDrugs Market, by Drug Class (Anti-infective, Antineoplastic, Diuretics, ProtonPump Inhibitor, Anesthetic, Anticoagulant, NSAID’s, and Others), by Indication(Infectious Disease, Autoimmune Disease, Gastrointestinal Disease, Cancer, andOthers), by Packaging Type (Vial, Injection, and Cartridge), and by region(North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -Global Forecast to 2026".
Increasing regulatory approvalfor lyophilized drug is contributing to lyophilized drugs market growth. Forinstance, in September 2018, Novartis Pharmaceuticals Corporation received theU.S. Food and Drug Administration approval for its Xolair (omalizumab)prefilled syringe formulation, for the treatment of moderate to severepersistent allergic asthma and chronic idiopathic urticarial. The drug is availablein a 150 mg single-dose vial with lyophilized, sterile powder forreconstitution. Moreover, increasing investments and facility expansion isexpected to show significant growth for the global lyophilized drugs market.
In August 2016, Dalton PharmaServices completed an investment of US$ 5 million for expansion of its sterilefilling and active pharmaceutical ingredient (API) manufacturing facility atits current good manufacturing practices (cGMP) facility in Toronto, Canada.This expansion project added three new sterile processing facilities, an APImanufacturing facility, and a semi-automated powder filling line with scale-upof lyophilization capacity.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/lyophilized-drugs-market-2930
Key Takeaways of the GlobalLyophilized Drugs Market:
The global lyophilized drugsmarket is expected to expand at a CAGR of 7.1% during the forecast period(2018–2026), owing to increasing initiatives by key players to developprominent technologies for patient identification
Increasing acquisitions by keyplayers for expanding lyophilized drugs business is expected to drive theglobal lyophilized drugs market growth. For instance, in November 2018,Argonaut Manufacturing Services, a contract development and manufacturingorganization (CDMO) serving molecular diagnostic and biopharmaceuticalcompanies, acquired LyoGen LLC. With this acquisition, Argonaut expanded itsreagent lyophilization capabilities from process development through productionscale deployment.
Major players operating in theglobal lyophilized drugs market include Sanofi S.A, Merck & Co., Inc.,Fresenius Kabi USA, LLC., Ciron Drugs & Pharmaceuticals Pvt Ltd.,GlaxoSmithKline plc., Mylan NV., Pfizer, Inc., Amneal Pharmaceuticals LLC,Otsuka Holdings Co., Ltd. (OtsukaPharmaceutical Co., Ltd.), and BTG Plc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2930
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
